Annual FCF
-$575.42 M
-$176.83 M-44.36%
31 December 2022
Summary:
Mirati Therapeutics annual free cash flow is currently -$575.42 million, with the most recent change of -$176.83 million (-44.36%) on 31 December 2022. During the last 3 years, it has fallen by -$176.83 million (-44.36%).MRTX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$143.75 M
-$11.63 M-8.80%
30 September 2023
Summary:
Mirati Therapeutics quarterly free cash flow is currently -$143.75 million, with the most recent change of -$11.63 million (-8.80%) on 30 September 2023.MRTX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$595.93 M
-$4.70 M-0.79%
30 September 2023
Summary:
Mirati Therapeutics TTM free cash flow is currently -$595.93 million, with the most recent change of -$4.70 million (-0.79%) on 30 September 2023.MRTX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MRTX Free Cash Flow Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | - | - | - |
3 y3 years | -44.4% | -2.2% | -49.5% |
5 y5 years | -285.5% | -232.5% | -299.2% |
MRTX Free Cash Flow High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3 years | ||||||
5 y | 5 years | ||||||
alltime | all time | -5558.3% | -1030.9% | -5752.8% |
Mirati Therapeutics Free Cash Flow History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sept 2023 | - | -$143.75 M(+8.8%) | -$595.93 M(+0.8%) |
June 2023 | - | -$132.12 M(-30.6%) | -$591.23 M(-2.2%) |
Mar 2023 | - | -$190.45 M(+46.9%) | -$604.26 M(+5.0%) |
Dec 2022 | -$575.42 M(+44.4%) | -$129.61 M(-6.8%) | -$575.42 M(-1.9%) |
Sept 2022 | - | -$139.05 M(-4.2%) | -$586.45 M(+18.1%) |
June 2022 | - | -$145.15 M(-10.2%) | -$496.44 M(+10.6%) |
Mar 2022 | - | -$161.61 M(+14.9%) | -$448.68 M(+12.6%) |
Dec 2021 | -$398.60 M(+44.5%) | -$140.63 M(+186.8%) | -$398.60 M(+18.7%) |
Sept 2021 | - | -$49.04 M(-49.6%) | -$335.89 M(-8.0%) |
June 2021 | - | -$97.40 M(-12.7%) | -$365.05 M(+11.2%) |
Mar 2021 | - | -$111.52 M(+43.1%) | -$328.19 M(+19.0%) |
Dec 2020 | -$275.90 M(+84.8%) | -$77.93 M(-0.3%) | -$275.90 M(+14.4%) |
Sept 2020 | - | -$78.20 M(+29.2%) | -$241.21 M(+23.0%) |
June 2020 | - | -$60.54 M(+2.2%) | -$196.03 M(+12.6%) |
Mar 2020 | - | -$59.23 M(+37.0%) | -$174.02 M(+16.6%) |
Dec 2019 | -$149.28 M(+112.6%) | -$43.23 M(+30.9%) | -$149.28 M(+17.6%) |
Sept 2019 | - | -$33.02 M(-14.3%) | -$126.92 M(+11.2%) |
June 2019 | - | -$38.54 M(+11.8%) | -$114.11 M(+17.9%) |
Mar 2019 | - | -$34.48 M(+65.1%) | -$96.75 M(+37.8%) |
Dec 2018 | -$70.22 M(+8.4%) | -$20.88 M(+3.3%) | -$70.22 M(+11.3%) |
Sept 2018 | - | -$20.21 M(-4.6%) | -$63.10 M(+8.8%) |
June 2018 | - | -$21.18 M(+166.5%) | -$57.99 M(+6.4%) |
Mar 2018 | - | -$7.95 M(-42.3%) | -$54.50 M(-15.9%) |
Dec 2017 | -$64.79 M(-5.0%) | -$13.77 M(-8.8%) | -$64.79 M(-3.7%) |
Sept 2017 | - | -$15.09 M(-14.7%) | -$67.28 M(-4.6%) |
June 2017 | - | -$17.70 M(-2.9%) | -$70.50 M(+1.5%) |
Mar 2017 | - | -$18.23 M(+12.2%) | -$69.45 M(+1.8%) |
Dec 2016 | -$68.21 M(+33.6%) | -$16.26 M(-11.2%) | -$68.21 M(+0.3%) |
Sept 2016 | - | -$18.32 M(+10.0%) | -$68.02 M(+3.7%) |
June 2016 | - | -$16.64 M(-2.1%) | -$65.57 M(+12.6%) |
Mar 2016 | - | -$17.00 M(+5.8%) | -$58.25 M(+14.1%) |
Dec 2015 | -$51.04 M(+54.1%) | -$16.06 M(+1.2%) | -$51.04 M(+17.0%) |
Sept 2015 | - | -$15.87 M(+70.3%) | -$43.63 M(+16.6%) |
June 2015 | - | -$9.32 M(-4.9%) | -$37.44 M(+9.7%) |
Mar 2015 | - | -$9.79 M(+13.2%) | -$34.13 M(+3.0%) |
Dec 2014 | -$33.13 M | -$8.65 M(-10.5%) | -$33.13 M(+2.9%) |
Sept 2014 | - | -$9.67 M(+61.0%) | -$32.20 M(+16.0%) |
June 2014 | - | -$6.01 M(-31.7%) | -$27.76 M(-10.5%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2014 | - | -$8.80 M(+14.0%) | -$31.03 M(+4.6%) |
Dec 2013 | -$29.66 M(+75.7%) | -$7.72 M(+47.5%) | -$29.66 M(+8.7%) |
Sept 2013 | - | -$5.24 M(-43.6%) | -$27.29 M(+3.9%) |
June 2013 | - | -$9.27 M(+24.8%) | -$26.25 M(+32.3%) |
Mar 2013 | - | -$7.43 M(+38.9%) | -$19.85 M(+17.6%) |
Dec 2012 | -$16.88 M(+47.7%) | -$5.35 M(+27.3%) | -$16.88 M(+11.1%) |
Sept 2012 | - | -$4.20 M(+46.5%) | -$15.19 M(+13.1%) |
June 2012 | - | -$2.87 M(-35.8%) | -$13.44 M(+4.2%) |
Mar 2012 | - | -$4.46 M(+21.9%) | -$12.89 M(+12.8%) |
Dec 2011 | -$11.43 M(-27.3%) | -$3.66 M(+49.5%) | -$11.43 M(+11.8%) |
Sept 2011 | - | -$2.45 M(+5.5%) | -$10.22 M(-15.3%) |
June 2011 | - | -$2.32 M(-22.8%) | -$12.08 M(-3.9%) |
Mar 2011 | - | -$3.00 M(+22.5%) | -$12.57 M(-20.1%) |
Dec 2010 | -$15.73 M(-23.3%) | -$2.45 M(-43.0%) | -$15.73 M(-4.4%) |
Sept 2010 | - | -$4.30 M(+53.0%) | -$16.46 M(-12.5%) |
June 2010 | - | -$2.81 M(-54.4%) | -$18.80 M(-11.9%) |
Mar 2010 | - | -$6.17 M(+94.1%) | -$21.35 M(+4.1%) |
Dec 2009 | -$20.50 M(+10.1%) | -$3.18 M(-52.1%) | -$20.50 M(+8.9%) |
Sept 2009 | - | -$6.64 M(+24.0%) | -$18.84 M(+10.2%) |
June 2009 | - | -$5.36 M(+0.7%) | -$17.09 M(-4.3%) |
Mar 2009 | - | -$5.32 M(+252.2%) | -$17.86 M(-4.1%) |
Dec 2008 | -$18.63 M(-22.3%) | -$1.51 M(-69.1%) | -$18.63 M(-24.8%) |
Sept 2008 | - | -$4.90 M(-20.2%) | -$24.79 M(+4.6%) |
June 2008 | - | -$6.13 M(+0.7%) | -$23.71 M(-4.9%) |
Mar 2008 | - | -$6.09 M(-20.6%) | -$24.94 M(+4.0%) |
Dec 2007 | -$23.97 M(-327.4%) | -$7.67 M(+100.9%) | -$23.97 M(+28.4%) |
Sept 2007 | - | -$3.82 M(-48.2%) | -$18.67 M(+43.5%) |
June 2007 | - | -$7.36 M(+43.7%) | -$13.00 M(+29.7%) |
Mar 2007 | - | -$5.13 M(+117.2%) | -$10.02 M(-195.1%) |
Dec 2006 | $10.54 M(-183.3%) | -$2.36 M(-227.8%) | $10.54 M(+1.4%) |
Sept 2006 | - | $1.85 M(-142.1%) | $10.40 M(+101.9%) |
June 2006 | - | -$4.39 M(-128.4%) | $5.15 M(-4.2%) |
Mar 2006 | - | $15.44 M(-716.5%) | $5.38 M(-142.5%) |
Dec 2005 | -$12.65 M(+85.2%) | -$2.50 M(-26.4%) | -$12.65 M(+24.7%) |
Sept 2005 | - | -$3.40 M(-18.2%) | -$10.15 M(+50.4%) |
June 2005 | - | -$4.16 M(+60.7%) | -$6.75 M(+160.7%) |
Mar 2005 | - | -$2.59 M | -$2.59 M |
Dec 2004 | -$6.83 M(-1314.2%) | - | - |
Dec 2003 | $562.60 K | - | - |
FAQ
- What is Mirati Therapeutics annual free cash flow?
- What is the all time high annual FCF for Mirati Therapeutics?
- What is Mirati Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Mirati Therapeutics?
- What is Mirati Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Mirati Therapeutics?
What is Mirati Therapeutics annual free cash flow?
The current annual FCF of MRTX is -$575.42 M
What is the all time high annual FCF for Mirati Therapeutics?
Mirati Therapeutics all-time high annual free cash flow is $10.54 M
What is Mirati Therapeutics quarterly free cash flow?
The current quarterly FCF of MRTX is -$143.75 M
What is the all time high quarterly FCF for Mirati Therapeutics?
Mirati Therapeutics all-time high quarterly free cash flow is $15.44 M
What is Mirati Therapeutics TTM free cash flow?
The current TTM FCF of MRTX is -$595.93 M
What is the all time high TTM FCF for Mirati Therapeutics?
Mirati Therapeutics all-time high TTM free cash flow is $10.54 M